We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...

Training a foundation LLM from scratch costs millions and requires internet-scale data — which is why most enterprises don't bother. Sapient thinks it has a cheaper path. To overcome this brute-force ...

The mockup marks an upgrade from the destroyer and aircraft carrier replicas previously identified at the Taklamakan Desert ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...